Displaying 1–16 of 16 results for Emil W. Ciurczak, Chief Technical Officer, Cadrai Group

Sort By Relevance Sort By Date

Silencing the cGMP Priesthood

(Article)

cGMPS are essential, but when cGMP dogma triumphs over common sense and prevents innovation, we’re all in trouble, says NIR expert and pharmaceutical industry consultant, Emil Ciurczak. He offers some tips for drawing the line between compliance and absurdity.

PAT in Perspective: Are We Being Spoiled by Success and the Internet?

(Article)

NIR expert Emil Ciurczak thinks prosperity and the Internet are making today's graduates far too complacent and out of touch for their own good. Networking and professional societies are at risk, he says, and drug manufacturing will be worse off for it.

PAT in Perspective: Do We Need Final Release Tests with PAT?

(Article)

NIR expert Emil Ciurczak asks whether PAT will eliminate the need for traditional USP product release tests…and concludes that they’re still essential as a reference method and important in minimizing liability.

PAT in Perspective: “One Size Fits All” Software May Not Fit PAT

(Article)

Beware of process control software that is not PAT-specific, cautions Emil Ciurczak. He cites Excel, with its rounding errors, as a prime example of software written without the input of “science-types.”

PAT in Perspective: Give Credit Where Credit is Due

(Article)

PAT and analytical services don’t always mix, as PAT columnist Emil Ciurczak relates. His advice: Don’t allow your PAT group to become a stepchild. Ensure that it receives credit for PAT-based improvements.

Ciurczak Analyzes IFPAC '06

(Article)

NIR expert and Pharmaceutical Manufacturing columnist Emil Ciurczak discusses this year's conference in this downloadable audio file. For his article discussing highlights and key developments, see "IFPAC 2006 Under the Microscope."

IFPAC 2006 Under the Microscope

(Article)

"NIR person" and physical chemist Emil Ciurczak provides a thorough analysis of this year's IFPAC conference, held Feb. 21-23 in Arlington, Va.

Urban Legends and Misconceptions

(Article)

Columnist Emil Ciurczak urges pharmaceutical manufacturers to realize that FDA personnel and instrument vendors are on their side, and that talking with them about PAT will be more fruitful than relying on word of mouth.

PAT in Perspective: Headcount and PAT—Fact and Fiction

(Article)

Attention, corporate bean counters: PAT is not a magic bullet for reducing QC headcounts. In fact, it may require hiring more people, but the efforts will pay off in improved efficiencies and lower costs.

IQPC’s Philly Conference Focuses on ROI, Management Issues

(Article)

Emil Ciurczak reviews December’s conference, which broke with tradition by focusing more on the business than the technical side of PAT.

PAT in Perspective: Estimate PAT’s Real Costs

(Article)

Don’t be “penny-wise but pound-foolish” during early planning and budgeting stages, and never base decisions on equipment sticker prices without considering savings in time to market.

PAT in Perspective: To Outsource or Not to Outsource . . .

(Article)

Pharmaceutical processing & engineering: A consultant ponders the question, as it relates to NIR and pharmaceutical process analytical technology (PAT) projects that require a high level of hard-to-find technical expertise.

PAT in Perspective: Preaching to the Wrong Choir

(Article)

Pharmaceutical processing & engineering: Last year at the IFPAC conference, NIR guru Emil Ciurczak bemoaned the fact that PAT was being promoted by geeks for geeks. Now, however, he notes that an upcoming summit may lead the charge toward a new emphasis on convincing corporate and financial ...

Sort By Relevance Sort By Date